Posts by: Inês Martins PhD

Inês Martins PhD

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

January 16, 2018

Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for Glioblastoma

News

Incysus has submitted its second investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of its gamma-delta T-cell immunotherapy candidate ... Read more

January 15, 2018

Inovio and Parker Institute to Collaborate on Bladder Cancer Immunotherapies

News

Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy will collaborate on combination therapies for muscle-invasive bladder cancer. They will use Inovio’s ASPIRE immunotherapy platform to develop the immuno-oncology combo regimens. The ... Read more

January 10, 2018

Lycera Starts Phase 1b Trial of Non-small Cell Lung Cancer Combo Therapy

News

Lycera has started a Phase 1b clinical trial to assess the safety of a combination of its immunotherapy LYC-55716 and Merck’s Keytruda (pembrolizumab) as a lung cancer therapy. The trial will involve patients whose non-small cell ... Read more

January 8, 2018

Targovax’s Cancer Immunotherapy TG02 Is Safe, Initial Trial Review Shows

News

Targovax’s immunotherapy for solid tumors has passed its first clinical trial safety review. The company is conducting a Phase 1b trial of TG02 alone, and in combination with Merck’s Keytruda (pembrolizumab), as a treatment for ... Read more

December 18, 2017December 18, 2017

OSE Immunotherapeutics Receives Grant to Explore New Cytotoxic Antibodies

News

A monoclonal antibody called OSE-703 will be OSE Immunotherapeutics’ main focus in a research program that recently received funding from the French government. Of a total cost of $2.8 million, the Fonds Unique ... Read more

December 15, 2017December 15, 2017

Bluebird Bio, TC BioPharm Partner to Develop Gamma Delta CAR T-cell Therapy Candidates

News

Bluebird bio and TC BioPharm recently announced a new partnership to develop gamma delta CAR T-cell product candidates for the treatment of cancer. The collaboration and licensing agreement were established to ... Read more

December 11, 2017

Health Canada OKs Start of Enrollment in Phase 2 DPX-Survivac Trial for DLBCL

News

Sunnybrook Research Institute received regulatory clearance from Health Canada to begin patient recruitment for a new clinical study evaluating a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B-cell ... Read more

December 7, 2017

$5M CIRM Grant Awarded to Continue Development of CD47 Antibody to Treat AML and MDS

News

Forty Seven, a clinical-stage immuno-oncology company, received a $5 million research grant from the California Institute for Regenerative Medicine (CIRM) to continue the development of its CD47 antibody Hu5F9-G4 in an ongoing clinical ... Read more

November 27, 2017November 27, 2017

Seattle Children’s $1B Fundraising Campaign Focuses on Immuno-Oncology Research

News

Seattle Children’s recently launched a $1 billion initiative aimed at transforming children’s health by investing in innovative research and immuno-oncology. Last year, Seattle Children’s received more than 420,000 visitors — ... Read more

November 13, 2017November 13, 2017

Boehringer Ingelheim, Sarah Cannon Research Institute to Study New Combo Therapy

News

Boehringer Ingelheim and Sarah Cannon Research Institute will jointly evaluate a SMAC mimetic candidate alone and in combination with an anti-PD-1 immunotherapy for the treatment of solid tumors. The two ... Read more